Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Dong Li, Jianqing Xu, Zhuozhi Wang, Zhen Gong, Jieying Liu, Yong Zheng, Jian Li & Jing Li. (2017) Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1. mAbs 9:4, pages 628-637.
Read now
Read now
Gerhard Hamilton & Barbara Rath. (2017) Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opinion on Biological Therapy 17:4, pages 515-523.
Read now
Read now
Articles from other publishers (26)
Walid Shalata, Zoé Gabrielle Attal, Rajeh Shhadi, Amjad Abu Salman, Ashraf Abu Jama, Sondos Shalata, Kais Halumi & Alexander Yakobson. (2023) Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review. Medicina 59:11, pages 1946.
Crossref
Crossref
Marzieh Nikoo, Fatemeh Rabiee, Hossein Mohebbi, Negar Eghbalifard, Hamid Rajabi, Yalda Yazdani, Delaram Sakhaei, Mohammadreza Khosravifarsani & Reza Akhavan-Sigari. (2023) Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. International Immunopharmacology 117, pages 109881.
Crossref
Crossref
Morten Fink, Anders Schwartz Vittrup, Lars Bastholt, Inge Marie Svane, Marco Donia, Adam A. Luczak, Christina H. Ruhlmann, Louise Mahncke Guldbrandt, Ulrich Heide Koehler, Mette Lerche Winther, Eva Ellebaek, Charlotte Aaquist Haslund & Henrik Schmidt. (2021) Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers 13:21, pages 5550.
Crossref
Crossref
Náthali Felícia Mineiro dos Santos Garrett, Ana Cristina Carvalho da Costa, Elaine Barros Ferreira, Giovanni Damiani, Paula Elaine Diniz dos Reis & Christiane Inocêncio Vasques. (2021) Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis. PLOS ONE 16:8, pages e0255716.
Crossref
Crossref
Koichi Ando, Yasunari Kishino, Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori, Tsukasa Ohnishi & Hironori Sagara. (2020) Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. Cancers 12:7, pages 1905.
Crossref
Crossref
Massimo Ralli, Andrea Botticelli, Irene Claudia Visconti, Diletta Angeletti, Marco Fiore, Paolo Marchetti, Alessandro Lambiase, Marco de Vincentiis & Antonio Greco. (2020) Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. Journal of Immunology Research 2020, pages 1-12.
Crossref
Crossref
Tibor Bakacs, Ralph W. Moss, Ralf Kleef, Marcell A. Szasz & Colin C. Anderson. (2019) Exploiting autoimmunity unleashed by low‐dose immune checkpoint blockade to treat advanced cancer. Scandinavian Journal of Immunology 90:6.
Crossref
Crossref
Filipe Martins, Latifyan Sofiya, Gerasimos P. Sykiotis, Faiza Lamine, Michel Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex-Crosier, Thierry Kuntzer, Olivier Michielin, Solange Peters, Georges Coukos, Francois Spertini, John A. Thompson & Michel Obeid. (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology 16:9, pages 563-580.
Crossref
Crossref
Amr Menshawy, Abdelrahman A. Eltonob, Sarah A. Barkat, Ahmed Ghanem, Mahmoud M. Mniesy, Ishak Mohamed, Mohamed Abdel-Maboud, Omar M. Mattar, Mohamed Elfil, Eshak I. Bahbah & Ahmed Elgebaly. (2018) Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials. Melanoma Research 28:5, pages 371-379.
Crossref
Crossref
J.-Matthias Löhr, Maximilian Kordes, Maria Gustafsson-Liljefors, Sam Ghazi, Nikolaos Kartalis, Valtteri Wirta, Jan-Eric Frödin, Thilo Hackert, Stephan Brock, Katrin Stecker, Caroline Huelsewig, Lars Ernstrand, Johan Permert & Dirk Jäger. (2018) Ein Fall von PankreaskarzinomA case of pancreatic carcinoma. Forum 33:4, pages 232-235.
Crossref
Crossref
Pedro R. Lowenstein & Maria G. Castro. (2018) Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Clinical Immunology 189, pages 43-51.
Crossref
Crossref
Michael Constantin Kirchberger & Lucie Heinzerling. 2018. Melanoma. Melanoma
577
589
.
Isabel Corraliza-Gorjón, Beatriz Somovilla-Crespo, Silvia Santamaria, Jose A. Garcia-Sanz & Leonor Kremer. (2017) New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology 8.
Crossref
Crossref
Jijie Gu, Andrew McCluskey & Tariq Ghayur. 2017. Protein Therapeutics. Protein Therapeutics
229
270
.
T L Whiteside. (2017) Exosomes carrying immunoinhibitory proteins and their role in cancer. Clinical and Experimental Immunology 189:3, pages 259-267.
Crossref
Crossref
Yajuan Zhou, Jingjing Miao, Haijun Wu, Hao Tang, Jing Kuang, Xiaoyi Zhou, Yi Peng, Desheng Hu, Dingbo Shi, Wuguo Deng, Xinyue Cao, Chong Zhao & Conghua Xie. (2017) PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes. Oncotarget 8:31, pages 51210-51223.
Crossref
Crossref
Hyosun Cho, Hyojeung Kang, Hwan Lee & Chang Kim. (2017) Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. International Journal of Molecular Sciences 18:7, pages 1517.
Crossref
Crossref
Jessica C. Hassel, Lucie Heinzerling, Jens Aberle, Oliver Bähr, Thomas K. Eigentler, Marc-Oliver Grimm, Victor Grünwald, Jan Leipe, Niels Reinmuth, Julia K. Tietze, Jörg Trojan, Lisa Zimmer & Ralf Gutzmer. (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treatment Reviews 57, pages 36-49.
Crossref
Crossref
Caroline Prieux-Klotz, Marie Dior, Diane Damotte, Johann Dreanic, Bertrand Brieau, Catherine Brezault, Vered Abitbol, Stanislas Chaussade & Romain Coriat. (2017) Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. Targeted Oncology 12:3, pages 301-308.
Crossref
Crossref
Myint Aung Win, Kyaw Zin Thein & Sai-Ching Jim Yeung. (2017) Cancer immunotherapy-induced posterior reversible encephalopathy syndrome in an ED. The American Journal of Emergency Medicine 35:4, pages 663.e1-663.e2.
Crossref
Crossref
Francesca Maria Bosisio & Joost J. van den Oord. (2017) Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Archiv 470:4, pages 357-369.
Crossref
Crossref
Yajuan Zhou, Dingbo Shi, Jingjing Miao, Haijun Wu, Jiewei Chen, Xiaoyi Zhou, Desheng Hu, Chong Zhao, Wuguo Deng & Conghua Xie. (2017) PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load. Scientific Reports 7:1.
Crossref
Crossref
Lucie Heinzerling & Simone M. Goldinger. (2017) A review of serious adverse effects under treatment with checkpoint inhibitors. Current Opinion in Oncology 29:2, pages 136-144.
Crossref
Crossref
B. Bonavida & S. Chouaib. (2017) Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. Annals of Oncology 28:3, pages 457-467.
Crossref
Crossref
Viera Bajčiová. (2016) Malignant melanoma and new options of treatment. Onkologie 10:6, pages 256-262.
Crossref
Crossref
Theresa Whiteside. (2016) Tumor-Derived Exosomes and Their Role in Tumor-Induced Immune Suppression. Vaccines 4:4, pages 35.
Crossref
Crossref